Initial 16 week data released on June 4th, concentrated on...

Initial 16 week data released on June 4th, concentrated on dosage and safety. The 24 week data is the big one, concentrating on effectiveness.
http://clinicaltrials.gov/ct2/show/NCT00612898?term=apricitabine&rank=5

Now, this data is a lot more complex and detailed so they are spending some time collating it and analysing it and possibly talking to drug companies and the FDA about it. That's why it was not released in early August. Perhaps some of the data leaking from this is stimulating increased share buying.

Another point: the completed Phase II trial was on only 52 patients. This current Phase III trial is on 970 patients. Thus, the data from this is much more robust and will stimulate large drug company interest much more than pissy phase II data on a tiny group.

Get ready for news!